As pharma readies to deal with the landmark US Inflation Reduction Act (IRA), which establishes unprecedented powers for price controls in Medicare, a former government official asserts that industry is not likely to face a big financial hit but ought to address the issue of affordability in earnest or risk more drastic action.
In an interview during his recent visit to India, David Shulkin, former Secretary of the US Department of Veterans Affairs in the Trump Administration, stated that while the impact of...
The Departments of Defense and Veterans Affairs has been able negotiate drug prices for their health programs for decades. Any learnings you could share?
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?